
Vaccine Contract Manufacturing Market
Vaccine Contract Manufacturing Market Forecasts to 2030 - Global Analysis By Product (Recombinant Vector Vaccines, Inactivated Vaccines and Other Products), Type (Bacterial, Viral and Other Types), Scale of Operations, Process, Application, End User and By Geography

Years Covered |
2021-2030 |
Estimated Year Value (2023) |
US $3.51 BN |
Projected Year Value (2030) |
US $8.30 BN |
CAGR (2023 - 2030) |
13.1% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Vaccine Contract Manufacturing Market is accounted for $3.51 billion in 2023 and is expected to reach $8.30 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Vaccine contract manufacturing involves outsourcing the production of vaccines to third-party manufacturers. Pharmaceutical companies partner with contract manufacturing organizations (CMOs) to leverage their expertise, facilities, and resources for the efficient and scalable production of vaccines. This approach allows companies to focus on research, development, and marketing while ensuring timely and cost-effective manufacturing of vaccines. Contract manufacturers adhere to strict quality standards and regulatory requirements, providing assurance of safety and efficacy. This model enables flexibility in production capacity, accelerating the availability of vaccines to meet global demand, especially during pandemics or emergencies.
According to data published by the American Academy of Pediatrics in March 2022, more than 1 million people in the United States have long-term hepatitis B infections, and people who are infected with hepatitis B as a baby have a 90% chance of developing serious, chronic conditions like liver cancer in their lifetime.
Market Dynamics:
Driver:
Increasing demand for vaccines
The increasing demand for vaccines serves as a pivotal driver propelling the growth of the vaccine contract manufacturing market. As the global population continues to prioritize preventive healthcare measures, the need for efficient vaccine production escalates. Vaccine Contract Manufacturing offers pharmaceutical companies the flexibility to scale up production swiftly to meet this rising demand. Additionally, outsourcing manufacturing to specialized facilities enables companies to focus on research and development, accelerating vaccine innovation. Furthermore, partnerships with contract manufacturers streamline the production process, ensuring timely delivery of vaccines to the market.
Restraint:
Quality control challenges
Quality control challenges primarily stem from the need for strict adherence to regulatory standards, complex manufacturing processes, and the demand for high-volume production. Ensuring consistent product quality across various batches and facilities presents a significant hurdle. Additionally, the global distribution of manufacturing sites complicates standardization and oversight. Moreover, the urgency to meet production deadlines while maintaining stringent quality standards can lead to errors or oversights. Variability in raw materials and equipment further exacerbates these challenges.
Opportunity:
Global vaccine demand
The global vaccine contract manufacturing market presents a significant opportunity driven by the escalating demand for vaccines worldwide. With the advent of the COVID-19 pandemic and increased focus on vaccination, there's a pressing need for expanded production capacity. This market offers advantages such as flexibility, scalability, and cost-effectiveness, enabling swift responses to emerging infectious diseases and large-scale immunization campaigns. Outsourcing vaccine production mitigates the risks associated with in-house manufacturing, including regulatory compliance and resource allocation.
Threat:
Intellectual property issues
Many vaccines are protected by patents, trademarks, and trade secrets, limiting access to their production methods and technologies. This creates barriers for contract manufacturers seeking to enter the market or scale up production. Additionally, disputes over IP rights can lead to legal battles, delays, and increased costs for manufacturers. Lack of clarity or enforcement of IP laws can also discourage innovation and investment in new vaccine manufacturing technologies. Addressing these issues through clear licensing agreements and effective IP protection mechanisms is crucial for ensuring equitable access to vaccines and fostering a competitive contract manufacturing market.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the vaccine contract manufacturing market in several ways. Firstly, there was an unprecedented surge in demand for vaccine manufacturing services, leading to a strain on existing capacities and prompting the need for expansion and ramping up of production capabilities. Secondly, the urgency of vaccine development and distribution necessitated collaborations between pharmaceutical companies and contract manufacturers, driving growth in the contract manufacturing sector. Additionally, the focus on advanced technologies for vaccine production, such as mRNA technology, created new opportunities for contract manufacturers with specialized expertise.
The clinical segment is expected to be the largest during the forecast period
The clinical segment in the vaccine contract manufacturing market is witnessing robust growth due to increasing investments in vaccine development and clinical trials are driving demand for contract manufacturing services. Additionally, the surge in infectious diseases and pandemics has accelerated vaccine research, leading to a higher demand for manufacturing capacity. Moreover, advancements in biotechnology and immunology have widened the scope of vaccine development, further fueling growth in this segment. The clinical segment caters to early-stage trials, where speed and flexibility in manufacturing are crucial, making contract manufacturers’ indispensable partners for pharmaceutical companies.
The biotech companies segment is expected to have the highest CAGR during the forecast period
The Biotech Companies segment is experiencing robust growth because biotech firms are increasingly outsourcing manufacturing to specialized contract manufacturing organizations (CMOs) to focus on research and development. The demand for vaccines, driven by infectious disease outbreaks and the ongoing COVID-19 pandemic, is driving the need for expanded manufacturing capacity. Advancements in biotechnology are enabling the development of more complex vaccines, necessitating specialized manufacturing expertise. Additionally, the flexibility and scalability offered by CMOs allow biotech companies to respond quickly to changing market demands and regulatory requirements.
Region with largest share:
North America has witnessed significant growth in the vaccine contract manufacturing market due to the region’s boasting advanced biopharmaceutical infrastructure and expertise, attracting companies to outsource vaccine production. The COVID-19 pandemic has accelerated demand for vaccine manufacturing capabilities, prompting pharmaceutical firms to seek contract manufacturing services to meet global needs swiftly. Additionally, regulatory support and favourable government initiatives have fostered a conducive environment for vaccine manufacturing partnerships.
Region with highest CAGR:
The Asia-Pacific region has experienced significant growth due to the region manufacturing infrastructure coupled with a skilled workforce, making it an attractive destination for vaccine production outsourcing. Favourable government policies and incentives have encouraged multinational pharmaceutical companies to establish manufacturing facilities in the region. Moreover, the increasing demand for vaccines, driven by population growth and rising healthcare awareness, has further fueled market expansion. Furthermore, the COVID-19 pandemic has highlighted the importance of vaccine manufacturing capacity, prompting governments and companies to invest in expanding production capabilities in the Asia Pacific.
Key players in the market
Some of the key players in Vaccine Contract Manufacturing market include AGC Biologics, Ajinomoto Bio-Pharma Services, Catalent, Charles River Laboratories International Inc., CJ CheilJedang Corporation, CSL Seqirus, Curia Global, Emergent BioSolutions Inc., Fujifilm Holdings Corporation , Gedeon Richter (Richter-Helm BioLogics) , ICON PLC, IDT Biologika GmbH, KBI Biopharma, Lonza Group AG, Merck KGaA, Recipharm AB, Samsung Biologics and WuXi Biologics.
Key Developments:
In April 2024, Invenra Inc., an innovative leader in bispecific antibody technology, has announced a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.
In April 2024, Merck has launched the Aptegra CHO Genetic Stability Assay, which leverages whole-genome sequencing and bioinformatics to significantly accelerate customers’ biopharmaceutical safety testing, thereby helping to accelerate customers’ entry into commercial production.
Products Covered:
• Recombinant Vector Vaccines
• Inactivated Vaccines
• Toxoid-based Vaccines
• Synthetic Vaccines
• Conjugate Vaccines
• Attenuated Vaccines
• Subunit-based Vaccines
• DNA-based Vaccines
• Other Products
Types Covered:
Bacterial
Viral
Other Types
Scale of Operations Covered:
• Clinical
• Commercial
• Preclinical
Processes Covered:
• Downstream
• Upstream
• Separator
• Electrolyte
• Other Processes
Application Covered:
• Veterinary
• Human Use
• Other Applications
End Users Covered:
• Biotech Companies
• Research Institutes
• Pharmaceutical Companies
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Vaccine Contract Manufacturing Market, By Product
5.1 Introduction
5.2 Recombinant Vector Vaccines
5.3 Inactivated Vaccines
5.4 Toxoid-based Vaccines
5.5 Synthetic Vaccines
5.6 Conjugate Vaccines
5.7 Attenuated Vaccines
5.8 Subunit-based Vaccines
5.9 DNA-based Vaccines
5.10 Other Products
6 Global Vaccine Contract Manufacturing Market, By Type
6.1 Introduction
6.2 Bacterial
6.3 Viral
6.4 Other Types
7 Global Vaccine Contract Manufacturing Market, By Scale of Operations
7.1 Introduction
7.2 Clinical
7.3 Commercial
7.4 Preclinical
8 Global Vaccine Contract Manufacturing Market, By Process
8.1 Introduction
8.2 Downstream
8.2.1 Analytical and QC Studies
8.2.2 Fill and Finish
8.2.3 Packaging
8.2.4 Other Downstream Processes
8.3 Upstream
8.3.1 Bacterial Expression Systems
8.3.2 Baculovirus/Insect Expression Systems
8.3.3 Mammalian Expression Systems
8.3.4 Yeast Expression Systems
8.3.5 Other Upstream Processes
8.4 Separator
8.5 Electrolyte
8.6 Other Processes
9 Global Vaccine Contract Manufacturing Market, By Application
9.1 Introduction
9.2 Veterinary
9.3 Human Use
9.4 Other Applications
10 Global Vaccine Contract Manufacturing Market, By End User
10.1 Introduction
10.2 Biotech Companies
10.3 Research Institutes
10.4 Pharmaceutical Companies
10.5 Other End Users
11 Global Vaccine Contract Manufacturing Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 AGC Biologics
13.2 Ajinomoto Bio-Pharma Services
13.3 Catalent
13.4 Charles River Laboratories International Inc.
13.5 CJ CheilJedang Corporation
13.6 CSL Seqirus
13.7 Curia Global
13.8 Emergent BioSolutions Inc.
13.9 Fujifilm Holdings Corporation
13.10 Gedeon Richter (Richter-Helm BioLogics)
13.11 ICON PLC
13.12 IDT Biologika GmbH
13.13 KBI Biopharma
13.14 Lonza Group AG
13.15 Merck KGaA
13.16 Recipharm AB
13.17 Samsung Biologics
13.18 WuXi Biologics
List of Tables
1 Global Vaccine Contract Manufacturing Market Outlook, By Region (2021-2030) ($MN)
2 Global Vaccine Contract Manufacturing Market Outlook, By Product (2021-2030) ($MN)
3 Global Vaccine Contract Manufacturing Market Outlook, By Recombinant Vector Vaccines (2021-2030) ($MN)
4 Global Vaccine Contract Manufacturing Market Outlook, By Inactivated Vaccines (2021-2030) ($MN)
5 Global Vaccine Contract Manufacturing Market Outlook, By Toxoid-based Vaccines (2021-2030) ($MN)
6 Global Vaccine Contract Manufacturing Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
7 Global Vaccine Contract Manufacturing Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
8 Global Vaccine Contract Manufacturing Market Outlook, By Attenuated Vaccines (2021-2030) ($MN)
9 Global Vaccine Contract Manufacturing Market Outlook, By Subunit-based Vaccines (2021-2030) ($MN)
10 Global Vaccine Contract Manufacturing Market Outlook, By DNA-based Vaccines (2021-2030) ($MN)
11 Global Vaccine Contract Manufacturing Market Outlook, By Other Products (2021-2030) ($MN)
12 Global Vaccine Contract Manufacturing Market Outlook, By Type (2021-2030) ($MN)
13 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial (2021-2030) ($MN)
14 Global Vaccine Contract Manufacturing Market Outlook, By Viral (2021-2030) ($MN)
15 Global Vaccine Contract Manufacturing Market Outlook, By Other Types (2021-2030) ($MN)
16 Global Vaccine Contract Manufacturing Market Outlook, By Scale of Operations (2021-2030) ($MN)
17 Global Vaccine Contract Manufacturing Market Outlook, By Clinical (2021-2030) ($MN)
18 Global Vaccine Contract Manufacturing Market Outlook, By Commercial (2021-2030) ($MN)
19 Global Vaccine Contract Manufacturing Market Outlook, By Preclinical (2021-2030) ($MN)
20 Global Vaccine Contract Manufacturing Market Outlook, By Process (2021-2030) ($MN)
21 Global Vaccine Contract Manufacturing Market Outlook, By Downstream (2021-2030) ($MN)
22 Global Vaccine Contract Manufacturing Market Outlook, By Analytical and QC Studies (2021-2030) ($MN)
23 Global Vaccine Contract Manufacturing Market Outlook, By Fill and Finish (2021-2030) ($MN)
24 Global Vaccine Contract Manufacturing Market Outlook, By Packaging (2021-2030) ($MN)
25 Global Vaccine Contract Manufacturing Market Outlook, By Other Downstream Processes (2021-2030) ($MN)
26 Global Vaccine Contract Manufacturing Market Outlook, By Upstream (2021-2030) ($MN)
27 Global Vaccine Contract Manufacturing Market Outlook, By Bacterial Expression Systems (2021-2030) ($MN)
28 Global Vaccine Contract Manufacturing Market Outlook, By Baculovirus/Insect Expression Systems (2021-2030) ($MN)
29 Global Vaccine Contract Manufacturing Market Outlook, By Mammalian Expression Systems (2021-2030) ($MN)
30 Global Vaccine Contract Manufacturing Market Outlook, By Yeast Expression Systems (2021-2030) ($MN)
31 Global Vaccine Contract Manufacturing Market Outlook, By Other Upstream Processes (2021-2030) ($MN)
32 Global Vaccine Contract Manufacturing Market Outlook, By Separator (2021-2030) ($MN)
33 Global Vaccine Contract Manufacturing Market Outlook, By Electrolyte (2021-2030) ($MN)
34 Global Vaccine Contract Manufacturing Market Outlook, By Other Processes (2021-2030) ($MN)
35 Global Vaccine Contract Manufacturing Market Outlook, By Application (2021-2030) ($MN)
36 Global Vaccine Contract Manufacturing Market Outlook, By Veterinary (2021-2030) ($MN)
37 Global Vaccine Contract Manufacturing Market Outlook, By Human Use (2021-2030) ($MN)
38 Global Vaccine Contract Manufacturing Market Outlook, By Other Applications (2021-2030) ($MN)
39 Global Vaccine Contract Manufacturing Market Outlook, By End User (2021-2030) ($MN)
40 Global Vaccine Contract Manufacturing Market Outlook, By Biotech Companies (2021-2030) ($MN)
41 Global Vaccine Contract Manufacturing Market Outlook, By Research Institutes (2021-2030) ($MN)
42 Global Vaccine Contract Manufacturing Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
43 Global Vaccine Contract Manufacturing Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.